The GLP Journal

News

What's happening with GLP-1 availability, pricing, and the FDA's position on compounded products.

• 

  News

  Can Ozempic Cause Vision Loss? What the NAION Research Shows in 2026

  The eyesight scare, explained: what NAION is, what the 2024–2026 studies found, why Europe and the UK added warnings the U.S. label still lacks, and the symptoms that need same-day care.

  8 min read · Updated Sep 29, 2026

• 

  News

  Retatrutide and 'Research Peptides': Inside the GLP-1 Gray Market Crackdown

  Why Eli Lilly sued six sellers, what FDA warning letters say about 'research use only' labels, what Customs is seizing, and how to tell a legitimate GLP-1 source from a black-market vial.

  7 min read · Updated Sep 29, 2026

• 

  News

  GLP-1 Availability and Pricing: 2026 Update

  The current state of GLP-1 supply, insurance coverage, and pricing in 2026 — and what it means for patients.

  7 min read · Updated Sep 15, 2026

• 

  News

  Clarifying Compounded GLP-1s: What the FDA Has Said

  A plain-language explanation of the FDA's stance on compounded semaglutide and tirzepatide, and what it means for access.

  8 min read · Updated Sep 14, 2026